NEWS
  • BSI Super Bowl XLVI Viewing Events in NYC
    By:  Presented by Brewer Sports International and TR Luxury
    02/05/2012

    BSI and TR Luxury will host various Super Bowl viewing parties on February 5th, 2012 in New York City.
     
  • NFL Veterans Support Amarantus BioSciences Traumatic Brain Injury Research
    NFL Veterans Support Amarantus BioSciences Traumatic Brain Injury Research
    By:  Brewer Sports International
    01/09/2012

    SUNNYVALE, CA and MINNEAPOLIS, MN – January 9, 2012 – Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF), a first-in-class disease–modifying therapeutic protein, today announced a commitment by 11-year National Football League (NFL) Veteran and Pro Bowler Corey Chavous as well as former NFL safety and CEO of The Brewer Group Companies, Jack Brewer to support the further research of the treatments of Traumatic Brain Injury (TBI), including the current work being done by Amarantus BioSciences.
     
  • Join us for the MNF Experience Finale Introducing Peace and Sport USA
    By:  Brewer Sports International
    12/02/2011

    JBF Worldwide to introduce Peace and Sport USA during the Monday Night Football Experience Finale at the Samsung Experience in NYC on Monday, December 12th. The exclusive event is hosted by BSI, The Jack Brewer Foundation and TR Luxury Group and will benefit AmeriCares...
     
  • BSI Funds Amarantus BioSciences Traumatic Brain Injury Research
    By:  Brewer Sports International
    11/30/2011

    SUNNYVALE, CA and MINNEAPOLIS, MN – November 30, 2011 – Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF), a first-in-class disease–modifying therapeutic protein, today announced a commitment by Brewer Sports International (BSI) to fund a pre-clinical study evaluating MANF’s potential as a treatment for Traumatic Brain Injury (TBI). This funding will support the collaboration recently announced between Amarantus and Banyan Biomarkers.